Form 4: Odyssey Therapeutics SVP Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Senior Vice President of Strategy and Business Development, Collin M. Todd, was granted 93,904 stock options in Odyssey Therapeutics.
Summary
- Collin M. Todd, Senior Vice President of Strategy and Business Development at Odyssey Therapeutics, Inc., was granted 93,904 stock options.
- The options have an exercise price of $18.00 per share.
- The grant date for the options is May 7, 2026, with an expiration date of May 6, 2036.
- The options vest in 48 equal monthly installments starting June 7, 2026, contingent upon continued service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of executive interests with long-term shareholder value through equity-based compensation.
- Retention mechanism established via a 48-month vesting schedule.
Negatives
- Potential for future shareholder dilution upon the exercise of these options.
Risks
- Vesting is subject to the continued service of the reporting person, creating a dependency on key personnel retention.
Future Outlook
The options vest over a four-year period, indicating a long-term commitment to the company's strategic goals.
Industry Context
StockSavvy.ai notes that equity grants for senior executives in the biotechnology sector are standard practice to ensure leadership retention and alignment with long-term R&D and commercialization milestones.
Comparison to Industry Standards
- The 48-month vesting schedule is consistent with standard industry practices for executive equity compensation.
- The grant size is typical for a Senior Vice President role in a mid-stage biotechnology firm.
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of the first installment of options on June 7, 2026.
Key Dates
| Date | Description |
|---|---|
| 05/07/2026 | Transaction date of the stock option grant. |
| 06/07/2026 | First vesting date for the granted options. |
| 05/11/2026 | Date of filing. |
| 05/06/2036 | Expiration date of the stock options. |
Keywords
Odyssey Therapeutics, ODTX, Form 4, Stock Options, Insider Trading, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.